$ATNM headed to $6.00 to $12.00 ~
Actinium Announces Closing of $5 Million Registered Direct Offering of Common Stock
Marketwired Actinium Pharmaceuticals
Jun 9, 2015 4:00 PM
NEW YORK, NY--(Marketwired - June 09, 2015) - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the closing of its previously announced registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company's common stock at a purchase price of $2.60 per share. This financing was led by investor Dr. Phillip Frost.
Actinium anticipates using the net proceeds for general corporate purposes, including capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs.
Laidlaw & Company (UK) Ltd. acted as the sole placement agent with respect to the offering.
The securities were offered pursuant to the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission on Form S-3. A prospectus supplement relating to the offering is filed with the SEC and will be available free of charge on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained from Laidlaw & Company (UK) Ltd. 546 Fifth Avenue, New York, NY 10036, Attn: Syndicate Department, telephone: 212-953-4900, email: syndicate@laidlawltd.com, or from the above-mentioned SEC website.
Actinium Announces Closing of $5 Million Registered Direct Offering of Common Stock
Marketwired Actinium Pharmaceuticals
Jun 9, 2015 4:00 PM
NEW YORK, NY--(Marketwired - June 09, 2015) - Actinium Pharmaceuticals, Inc. ("Actinium" or the "Company"
(NYSE MKT: ATNM), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today the closing of its previously announced registered direct offering of $5.0 million of its common stock. Under the terms of the subscription agreements, the Company issued an aggregate of 1,923,078 shares of the Company's common stock at a purchase price of $2.60 per share. This financing was led by investor Dr. Phillip Frost. Actinium anticipates using the net proceeds for general corporate purposes, including capital expenditures, the advancement of our product candidates in clinical trials, such as Iomab™-B and Actimab-A, preclinical trials, to support licensing activities, and to meet working capital needs.
Laidlaw & Company (UK) Ltd. acted as the sole placement agent with respect to the offering.
The securities were offered pursuant to the Company's effective shelf registration statement previously filed with the Securities and Exchange Commission on Form S-3. A prospectus supplement relating to the offering is filed with the SEC and will be available free of charge on the SEC's website at www.sec.gov. Copies of the final prospectus relating to the offering may be obtained from Laidlaw & Company (UK) Ltd. 546 Fifth Avenue, New York, NY 10036, Attn: Syndicate Department, telephone: 212-953-4900, email: syndicate@laidlawltd.com, or from the above-mentioned SEC website.
My Favorite plays are on the Nasdaq DIP and RIP Board http://investorshangout.com/NASDAQ-DIP-and-RIP-87909/
My Favorite Paid chat room with amazing chart setups is The Trading Stock Lounge http://www.thetradingstocklounge.com/
My Favorite Paid chat room with amazing chart setups is The Trading Stock Lounge http://www.thetradingstocklounge.com/
